TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...
BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of just $7.91 million, and Quantum Leap Healthcare Collaborative announced Thursday a ...
CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech ...
(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage ...
In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...
BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...
Split designed to achieve compliance with Nasdaq minimum bid price requirements Logo (PRNewsfoto/TransCode Therapeutics, Inc.) The 1-for-28 reverse stock split will automatically convert twenty-eight ...
TransCode Therapeutics (NASDAQ:RNAZ) announces to raise $10M through the purchase and sale of 10.25M shares of its common stock and warrants to purchase up to 10.25M shares of common stock priced ...
Microsoft PowerToys is a free application that brings a bunch of advanced features to Windows for power users. Some of those tools give you more control over your mouse and keyboard settings. Others ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap biotech company with a market capitalization of $3.3 million and trading near its 52-week low, has received approval from its Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results